Enterome is a clinical stage company, pioneering the development of novel pharmaceuticals and diagnostics to support personalized therapies in microbiome-related diseases such as Inflammatory Bowel Disease (IBD), cancer and metabolic diseases.
Enterome develops science-based personalized medical tests and companion diagnostics based on profiling of the human gut microbiome with the goal to improve management of microbiome-related diseases, e.g., metabolic, gastrointestinal, and autoimmune. These chronic disorders depend on genetic susceptibility (polymorphisms of the human genome), but are also triggered by environmental factors where dysbiosis of the intestinal bacterial ecosystem (gut microbiome) is a major contributor.
Enterome was founded in 2011 and is based in Paris, Ile-de-France, France with with an additional office in Cambridge, Massachusetts.
Enterome has established partnerships with leading pharmaceutical companies and academic research institutes, including Johnson & Johnson Innovation/Janssen Biotech, Takeda and Abbvie in inflammatory bowel and gastro-intestinal diseases; Bristol-Myers Squibb in immuno-oncology; and the Mayo Clinic and Geisinger hospitals in metabolic disorders.
Enterome is backed by investors including Seventure Partners, European Investment Bank (EIB), Lundbeckfonden Ventures, & Nestlé Health Science among others.